In contrast, GLP-1 injectables, such as Ozempic, Wegovy, Zepbound, and Mounjaro, are prescription medications that help with weight loss in obesity and diabetes management
Because GLP-1 slows down digestion, some patients may experience mild gastrointestinal side effects like nausea, mild stomach discomfort, or changes in bowel habits, especially when first starting
These medications include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GIP/GLP-1 receptor agonist, not a pure GLP-1 agonist
Explore how these changes will impact coverage, access, and the competitive landscape for generics and biosimilars
Regulatory submissions are anticipated in late 2025 for obesity and in 2026 for type 2 diabetes [75]
As exendin(9-39) does not completely eliminate GLP-1 action, we tested the acute glucoregulatory actions of metformin in mice with genetic disruption of one or both incretin receptors
